Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients

Peritoneal Dialysis Clinical Trial

Official title: A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis

Status Recruiting

Clinical Trial Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the researchers investigated the hypothesis that NAC protect peritoneal membrane damage.

Clinical Trial Description

N-Acetylcysteine (NAC) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 1200 mg per day. Patients will be randomly assigned to NAC and control group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test (PET) will be performed with blood sampling. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• End-Stage Kidney Disease
• Kidney Diseases
• Kidney Failure, Chronic
• Peritoneal Dialysis

• NCT number: NCT01111422
• Study type: Interventional
• Source: Ewha Womans University
• Contact: Mina Yu, MD
• Phone: +82-2-2650-2562
• Email: yuelizabeth@hanmail.net
• Status: Recruiting
• Phase: Phase 4
• Start date: March 2010
• Completion date: December 2011